Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, the company believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Company profile
Ticker
MRKR
Exchange
Website
CEO
Peter Hoang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EDUVERSE COM, GENEMAX CORP, TAPIMMUNE INC, TAPIMMUNE INC.
SEC CIK
Corporate docs
Subsidiaries
Marker Cell Therapy, Inc. • GeneMax Pharmaceuticals, Inc. • GeneMax Pharmaceuticals Canada, Inc. ...
IRS number
880277072
MRKR stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
26 Jan 23
424B3
Prospectus supplement
3 Jan 23
EFFECT
Notice of effectiveness
3 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
29 Dec 22
S-1
IPO registration
23 Dec 22
8-K
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
13 Dec 22
8-K
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
22 Nov 22
8-K
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 18.08 mm | 18.08 mm | 18.08 mm | 18.08 mm | 18.08 mm | 18.08 mm |
| Cash burn (monthly) | 2.58 mm | 2.55 mm | 2.34 mm | 2.99 mm | 2.55 mm | 2.13 mm |
| Cash used (since last report) | 10.79 mm | 10.66 mm | 9.77 mm | 12.48 mm | 10.65 mm | 8.89 mm |
| Cash remaining | 7.29 mm | 7.41 mm | 8.30 mm | 5.59 mm | 7.43 mm | 9.19 mm |
| Runway (months of cash) | 2.8 | 2.9 | 3.5 | 1.9 | 2.9 | 4.3 |
Institutional ownership, Q3 2022
46.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 47 |
| Opened positions | 1 |
| Closed positions | 6 |
| Increased positions | 9 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 34.47 mm |
| Total shares | 38.67 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| New Enterprise Associates 16 | 14.46 mm | $26.90 mm |
| NEA Management | 10.71 mm | $3.95 mm |
| Eastern Capital | 3.97 mm | $0.00 |
| Aisling Capital Management | 3.14 mm | $1.16 mm |
| Vanguard | 1.77 mm | $651.00 k |
| Long Focus Capital Management | 1.46 mm | $539.00 k |
| Geode Capital Management | 579.10 k | $213.00 k |
| Matrix Asset Advisors | 400.00 k | $148.00 k |
| ACT Capital Management, LLLP | 354.40 k | $131.00 k |
| Ar Asset Management | 279.00 k | $103.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 May 22 | David Laskow-Pooley | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3377 | 80,000 | 27.02 k | 80,000 |
| 24 May 22 | Katharine Knobil | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3377 | 80,000 | 27.02 k | 80,000 |
| 24 May 22 | Norman David Eansor | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3377 | 80,000 | 27.02 k | 80,000 |
| 24 May 22 | Wilson John Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3377 | 80,000 | 27.02 k | 80,000 |
| 24 May 22 | Steve Elms | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3377 | 80,000 | 27.02 k | 80,000 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
26 Jan 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
25 Jan 23
12 Health Care Stocks Moving In Monday's After-Market Session
16 Jan 23
Stocks That Hit 52-Week Lows On Thursday
29 Dec 22
12 Health Care Stocks Moving In Wednesday's Intraday Session
23 Nov 22